A miRNA Risk Score for the Prediction of Response to Lenalidomide in Multiple Myeloma (MM) Patients

被引：0
|
作者：
Neri, Paola [1 ]
Belch, Andrew R. [2 ,3 ]
Johnson, Jordan [1 ]
Gratton, Kathy J. [1 ]
Ren, Li [1 ]
Duggan, Peter [1 ]
Mansoor, Adnan [4 ]
Stewart, Douglas A. [1 ]
Bahlis, Nizar [1 ]
机构：
[1] Univ Calgary, So Alberta Canc Res Inst, Div Hematol, Calgary, AB, Canada
[2] Univ Alberta, Edmonton, AB, Canada
[3] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[4] Univ Calgary, Div Hematol & Transfus Med, Calgary, AB, Canada
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：451 / 451
页数：1
相关论文
共 50 条
  • [21] COMPARISON OF RESPONSE DURATION (RPD) AFTER THALIDOMIDE, BORTEZOMIB AND LENALIDOMIDE ADMINISTRATION TO MULTIPLE MYELOMA (MM) PATIENTS; A SINGLE CENTER EXPERIENCE
    Kyrtsonis, M. C.
    Nikolaou, E.
    Maltezas, D.
    Koulieris, E.
    Iliakis, T.
    Sarris, K.
    Vyniou, E.
    Vardounioti, I.
    Efthymiou, A.
    Bitsani, K.
    Karali, V.
    Pessach, I.
    Bartzis, V.
    Tzenou, T.
    Dimou, M.
    Vassilakopoulos, T.
    Angelopoulou, M.
    Tsaftaridis, P.
    Panayiotidis, P.
    HAEMATOLOGICA, 2014, 99 : 646 - 646
  • [22] Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma
    Kourelis, T. V.
    Kumar, S. K.
    Srivastava, G.
    Gertz, M. A.
    Lacy, M. Q.
    Buadi, F. K.
    Kyle, R. A.
    Dispenzieri, A.
    LEUKEMIA, 2014, 28 (02) : 455 - 457
  • [23] Pharmacokinetic and bioequivalence of lenalidomide in multiple myeloma patients
    Shen, Qi
    Gao, Tiantao
    Xiang, Jin
    Feng, Ping
    Liu, Xinghong
    Zheng, Li
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2023, 61 (04) : 181 - 188
  • [24] Update on the role of lenalidomide in patients with multiple myeloma
    Holstein, Sarah A.
    Suman, Vera J.
    McCarthy, Philip L.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (07) : 175 - 190
  • [25] Lenalidomide Maintenance Therapy in Patients with Multiple Myeloma
    Fillitz, M.
    Seebacher, A.
    Reisner, R.
    Pittermann-Hocker, E.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S90 - S90
  • [26] Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma
    T V Kourelis
    S K Kumar
    G Srivastava
    M A Gertz
    M Q Lacy
    F K Buadi
    R A Kyle
    A Dispenzieri
    Leukemia, 2014, 28 : 455 - 457
  • [27] Population pharmacokinetics of lenalidomide in multiple myeloma patients
    Beatriz Guglieri-López
    Alejandro Pérez-Pitarch
    Dirk Jan A. R. Moes
    Begoña Porta-Oltra
    Mónica Climente-Martí
    Henk Jan Guchelaar
    Matilde Merino-Sanjuán
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 189 - 200
  • [28] Population pharmacokinetics of lenalidomide in multiple myeloma patients
    Guglieri-Lopez, Beatriz
    Perez-Pitarch, Alejandro
    Moes, Dirk Jan A. R.
    Porta-Oltra, Begona
    Climente-Marti, Monica
    Guchelaar, Henk Jan
    Merino-Sanjuan, Matilde
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (01) : 189 - 200
  • [29] Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction
    Astarita, Anna
    Mingrone, Giulia
    Airale, Lorenzo
    Vallelonga, Fabrizio
    Covella, Michele
    Catarinella, Cinzia
    Cesareo, Marco
    Bruno, Giulia
    Leone, Dario
    Giordana, Carlo
    Cetani, Giusy
    Salvini, Marco
    Gay, Francesca
    Bringhen, Sara
    Rabbia, Franco
    Veglio, Franco
    Milan, Alberto
    CANCERS, 2021, 13 (07)
  • [30] Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma
    Sanfilippo, Kristen M.
    Carson, Kenneth R.
    Wang, Tzu-Fei
    Luo, Suhong
    Edwin, Natasha
    Kuderer, Nicole
    Keller, Jesse M.
    Gage, Brian F.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2022, 6 (01)
12345